Introduction
GRAFT LOSS
The long-term survival of kidney grafts continues to be hampered by two reasons. First, conventional immunosuppressive therapy is still unable to prevent long-term kidney graft loss, and a significant proportion of patients lose their grafts due to chronic (antibody-mediated) rejection (We have previously published the results of a phase I trial using modified donor peripheral blood mononuclear cells (MIC) together with reduced standard immunosuppressive therapy to prevent rejection in 10 living donor kidney transplant recipients (